A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/29/2018 |
| Start Date: | June 2006 |
| End Date: | August 2007 |
A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens
Pharmacologic boosting of protease inhibitors with ritonavir has become standard practice in
antiretroviral therapy. Patients are instructed to take ritonavir at the same time as its
accompanying protease inhibitor. However, ritonavir is unpopular with many patients because
of its large size and because of the recommended need for refrigeration. This study will test
the hypothesis that adherence to ritonavir is inferior to adherence to its accompanying
protease inhibitor in patients receiving such therapy.
antiretroviral therapy. Patients are instructed to take ritonavir at the same time as its
accompanying protease inhibitor. However, ritonavir is unpopular with many patients because
of its large size and because of the recommended need for refrigeration. This study will test
the hypothesis that adherence to ritonavir is inferior to adherence to its accompanying
protease inhibitor in patients receiving such therapy.
The study staff will employ MEMS caps to prospectively measure adherence to ritonavir and its
accompanying protease inhibitor over 24 weeks of follow-up. Paired sample t-tests will be
employed to compare adherence to the two agents, and secondary analyses will be conducted to
evaluate the chronologic concordance of ritonavir and accompanying protease inhibitor dosing.
accompanying protease inhibitor over 24 weeks of follow-up. Paired sample t-tests will be
employed to compare adherence to the two agents, and secondary analyses will be conducted to
evaluate the chronologic concordance of ritonavir and accompanying protease inhibitor dosing.
Inclusion Criteria:
- HIV infection, age>18 years, receiving therapy with ritonavir-boosted atazanavir or
fosamprenavir, willingness to use MEMS caps, willingness to provide informed consent
Exclusion Criteria:
- Treatment with any medication that is contraindicated in combination with ritonavir or
its accompanying protease inhibitor
We found this trial at
1
site
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
Click here to add this to my saved trials
